Since its first clinical application in men in 1980 ICD therapy has been rapidly growing from the initial idea of secondary prevention to primary prevention. Also, the treatment of young patients with genetic electrical disorders with an increased risk for sudden cardiac death has led to an expansion of the indication.
This requires a stable and safe performance of all implanted components over decades to avoid life threatening complications in patients.
The leads, especially the ICD leads, which are more complex and challenging in their structure, have been identified as the weakest part in the whole system. Continuous mechanical stress, unfavourable anatomical findings and suboptimal puncture techniques may lead to lifethreatening defects of the electrodes. Even theoretical improvements in lead design have not always been transferred to an increased longevity of the leads, but required early recalls in some cases.
Device-related infections have been dramatically increased mainly due to repetitive replacements, upgrade procedures and a changing patient population which is increasingly marked by a higher comorbidity.
This issue addresses this problem, shows the current state of lead technology, analyses actual and historic lead problems and recalls and discusses alternatives. Strategies and clinical pathways prior to and post device explantation are discussed, techniques and tools for lead extraction are updated. Furthermore this issue focuses on the detection of device-related infections and their concomitant therapy.
The state-of-the-art of subcutaneous ICD treatment is analyzed, and advantages and disadvantages in comparison with transvenous ICD treatment are discussed.
Special attention should be paid to the article about the European Lead Extraction Registry called ELECTRa initiated by the EHRA. It is the first time that Europewide cross-institutional and cross-national monitored data about lead extraction are generated. These data will hopefully allow drawing specific conclusions on device-related complications and treatment. Out of 3500 intended patients to be included already more than 1000 have been registered up to now.
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